Analysts See $-1.50 EPS for Portola Pharmaceuticals, Inc. (PTLA)

July 13, 2018 - By Elizabeth Jones

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) LogoInvestors sentiment decreased to 0.89 in Q1 2018. Its down 0.47, from 1.36 in 2017Q4. It fall, as 37 investors sold Portola Pharmaceuticals, Inc. shares while 47 reduced holdings. 20 funds opened positions while 55 raised stakes. 55.00 million shares or 2.41% less from 56.35 million shares in 2017Q4 were reported.
State Of Wisconsin Inv Board reported 50,667 shares or 0% of all its holdings. Utd Services Automobile Association accumulated 126,784 shares. Panagora Asset Management reported 53,322 shares or 0.01% of all its holdings. Teachers Retirement Systems Of The State Of Kentucky invested in 0.01% or 29,801 shares. Nicholas Inv Prtn Limited Partnership, a California-based fund reported 39,490 shares. Amalgamated Natl Bank owns 0.01% invested in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) for 7,604 shares. 604,323 are owned by Credit Suisse Ag. 12,330 are held by Rothschild Corporation Il. Oppenheimer And invested in 0.02% or 21,599 shares. Fortaleza Asset Management holds 0.34% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) for 1,725 shares. Moreover, Loring Wolcott Coolidge Fiduciary Llp Ma has 0% invested in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) for 10 shares. First Personal Fincl Service holds 0.01% or 707 shares. Bnp Paribas Arbitrage invested 0% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Ubs Asset Americas holds 362,655 shares. Raymond James has 0% invested in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) for 19,861 shares.

Since March 12, 2018, it had 0 buys, and 2 insider sales for $274,822 activity. Shares for $43,663 were sold by Fu Tao on Monday, March 12.

Analysts expect Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) to report $-1.50 EPS on August, 8.They anticipate $0.28 EPS change or 22.95 % from last quarter’s $-1.22 EPS. After having $-1.28 EPS previously, Portola Pharmaceuticals, Inc.’s analysts see 17.19 % EPS growth. The stock increased 0.32% or $0.13 during the last trading session, reaching $40.17. About 303,338 shares traded. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has risen 7.75% since July 13, 2017 and is uptrending. It has underperformed by 4.82% the S&P500.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Ratings Coverage

Among 5 analysts covering Portola Pharma (NASDAQ:PTLA), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Portola Pharma had 10 analyst reports since January 15, 2018 according to SRatingsIntel. Oppenheimer maintained the stock with “Buy” rating in Monday, January 15 report. Credit Suisse maintained the stock with “Outperform” rating in Tuesday, March 13 report. The firm has “Equal-Weight” rating by Morgan Stanley given on Monday, May 7. The firm has “Buy” rating given on Friday, May 4 by Cowen & Co. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has “Equal-Weight” rating given on Thursday, March 1 by Morgan Stanley. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has “Outperform” rating given on Wednesday, February 21 by Credit Suisse. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has “Overweight” rating given on Thursday, February 22 by Morgan Stanley. The company was maintained on Thursday, May 17 by Oppenheimer. The firm earned “Buy” rating on Tuesday, March 13 by Oppenheimer.

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. The company has market cap of $2.64 billion. The firm is developing Betrixaban, an oral once-daily inhibitor of Factor Xa that is in Phase III clinical stage for extended duration VTE prophylaxis in acute medically ill patients for 35 days of in-hospital and post-discharge use; Andexanet alfa, a recombinant protein, which is in Phase III and IV stages for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, an orally available dual kinase inhibitor, which is in Phase IIa clinical stage for hematologic, blood, cancers, and inflammatory disorders. It currently has negative earnings. It also develops Syk-selective inhibitors in pre-clinical stage for allergic conjunctivitis.

More recent Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) news were published by: Investorplace.com which released: “5 Biotech Stocks That Could Be the Next Amgen” on June 27, 2018. Also Globenewswire.com published the news titled: “Portola Pharmaceuticals Appoints 30-Year Industry Veteran Glenn Brame as Senior Vice President of Technical …” on June 25, 2018. Globenewswire.com‘s news article titled: “Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)” with publication date: July 03, 2018 was also an interesting one.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.